Tudor Investment Corp
JANX icon

Tudor Investment Corp’s Janux Therapeutics JANX Stock Holding History

Tudor Investment Corp’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$413K Sell
29,689
-49,469
-62% -$678K ﹤0.01% 2947
2025
Q4 		$1.09M Sell
79,158
-19,398
-20% -$456K ﹤0.01% 2204
2025
Q3 		$2.41M Sell
98,556
-15,193
-13% -$370K ﹤0.01% 1681
2025
Q2 		$2.63M Sell
113,749
-60,601
-35% -$1.6M 0.01% 1479
2025
Q1 		$4.71M Buy
+174,350
New +$6.57M 0.02% 813
2024
Q3 		– Sell
-67,487
Closed -$2.83M – 2915
2024
Q2 		$2.83M Buy
67,487
+61,072
+952% +$2.87M 0.01% 885
2024
Q1 		$242K Buy
+6,415
New +$140K ﹤0.01% 1948

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tudor Investment Corp's JANX Position: Q1 2026 in Review

Tudor Investment Corp reduced its Janux Therapeutics (JANX) stake by 62% in Q1 2026, selling an estimated $678K and leaving 29,689 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #2947.

Tudor Investment Corp first reported a position in JANX in Q1 2024 and has held it in 7 quarters since. The position peaked at $4.71M in Q1 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Tudor Investment Corp held 29,689 shares of Janux Therapeutics worth $413K as of Q1 2026.
  • Tudor Investment Corp sold 49,469 Janux Therapeutics shares in Q1 2026, an estimated $678K.
  • Janux Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #2947 holding.
  • Tudor Investment Corp first reported a position in Janux Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Tudor Investment Corp's Janux Therapeutics position peaked at $4.71M in Q1 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.